The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy is the standard of care in treating advanced non-small cell lung cancer (NSCLC). Nevertheless, whether adding pemetrexed-based chemotherapy to EGFR-TKI targeted therapy furtherly prolongs survival outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bi-Cheng, Zhang, Wen-Xuan, Kuang, Bo-Hua, Lin, Guo-He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550038/
https://www.ncbi.nlm.nih.gov/pubmed/36215289
http://dx.doi.org/10.1371/journal.pone.0275919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550038/
https://www.ncbi.nlm.nih.gov/pubmed/36215289
http://dx.doi.org/10.1371/journal.pone.0275919

Ejemplares similares